Navigation Links
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
Date:5/8/2008

asis continues to be focused around 'Choice', the ability for Volcano to provide a number of different therapy enabling modalities, and letting the physician choose which technology is appropriate for each individual patient."

Christopher E. Banas, Vice President and General Manager of Volcano's OCT Division in San Antonio Texas, and former CEO and Chairman of CardioSpectra commented, "This is an important step in demonstrating the ability of Volcano's OCT catheter to safely image coronary vessels of human patients and establishing a leadership position in advanced coronary imaging technologies."

Volcano's OCT imaging platform provides high-resolution images in the 10- 15 micron range, opening the door for new applications to complement both IVUS and angiography. Michel Lussier, president of Volcano Europe commented, "The high resolution OCT images provide a glimpse at structural detail not seen before by other imaging modalities. We believe that OCT has the potential to identify thin-cap fibro-atheromas, clearly highlight intraluminal thrombus, and assess the complete healing of novel drug-eluting stent designs. Volcano is committed to exploring the various clinical benefits of our OCT platform through detailed data-driven study design and mutually beneficial partnerships with other therapy companies."

Patrick Serruys, M.D., commented, "The Volcano OCT Imaging Catheter is another step closer to delivering interventionalists with the true cath lab of the future. To better serve my patients, I want the flexibility to select from an array of different tools, quickly interrogate the vessel, and immediately process the information. Having these various technologies, including IVUS, OCT and FFR, all integrated into the lab, with a common user interface, review points, data storage and staff training provides this flexibility."

About Volcano Corporation

Volcano Corporation (NASDAQ:

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , May 29, 2015 ... the addition of the "2015 Assessments ... Major Suppliers and Recent Market Entrants" ... new 90-page report from VPGMarketResearch.com provides insightful ... recent market entrants. The report ...
(Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
(Date:5/31/2015)... , June 1, 2015 ... rare diseases, has selected Veeva Commercial Cloud to ... and medical. A complete solution, Veeva Commercial ... and compliant content to provide a comprehensive view ... execution.      (Logo: http://photos.prnewswire.com/prnh/20120425/527164) , ...
(Date:5/31/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... and drug-delivery therapies, today announced interim findings from ... investigational new drug PEGPH20 for the potential treatment ... The encouraging interim data was presented today at ... in an oral presentation by Principal Investigator ...
Breaking Biology Technology:Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... , MADEIRA BEACH, Fla. , ... – Mr. Diabetes®, Executive Director of Defeat Diabetes Foundation and ... the ProtoKinetix (PKTX) Advisory Board.  ProtoKinetix, Inc. is a biotechnology ... anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic ...
... , Editors say the new mission statement ... of biological research , BETHESDA, Md. , Jan. 14 ... week a number of changes to the journal,s publishing policies. They ... of biological research and will help the journal better meet the ...
... , , , , ... Sweden , January 14 Karolinska,Development AB and ... enrich the flow of investment opportunities available to,Karolinska Development and ... agreement involves evaluation of,potential investments; advise to existing portfolio companies ...
Cached Biology Technology:Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board 2Journal of Biological Chemistry Changes Approach to Manuscript Reviews and Eliminates Submission Fees 2Journal of Biological Chemistry Changes Approach to Manuscript Reviews and Eliminates Submission Fees 3Karolinska Development and Uminova Invest Sign Co-operation Agreement 2
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... break down cellulose (chunks of wood pulp), a process ... chemicals like chlorine. Nature performs the same task using ... far less energy. The catch is that the enzymes ... hold up to the high temperatures of the manufacturing ...
... Technology (NIST) and in Lithuania have used a NIST-developed ... detect and measure a protein associated with a serious ... The work illustrates how the artificial membrane could be ... bacteria Gardnerella vaginalis , BV is a very ...
... This news release is available in German . ... the death of thousands of neurons in the brain. Nerve growth ... of the neurons; however, clinical tests with GDNF have not yielded ... Neurobiology in Martinsried and their colleagues have now succeeded in demonstrating ...
Cached Biology News:Expanding the range of nature's catalysts for industrial applications 2Expanding the range of nature's catalysts for industrial applications 3NIST cell membrane model studied as future diagnostic tool 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
... Most sensitive silver stain. ... stop baths or reversers needed. ... and polysaccharides. Linear protein-to-stain ... stain multiple gels per tray. ...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Biology Products: